Lymphoma, Leukemia & Myeloma Congress News

networking at LL&M Congress

What Is Changing in Philadelphia Chromosome-Positive ALL?

Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has evolved dramatically over the past decade

News & Insights

attendee in session

Is DLBCL Entering the Post-R-CHOP Era?

For more than two decades, R-CHOP has been the standard frontline treatment for diffuse large B-cell lymphoma (DLBCL). However, a wave of

man speaking during session

Frontline Hodgkin Lymphoma: Should Every Patient Receive Checkpoint Inhibitor-Based Therapy?

Checkpoint inhibitors are rapidly reshaping the frontline treatment landscape for classical Hodgkin lymphoma (cHL). Recent clinical trial

speaker on the stage

Could MRD Become the Most Important Tool in Acute Leukemia Management?

Measurable residual disease (MRD) has rapidly evolved from a prognostic marker to one of the most influential tools in acute leukemia

man speaking during the Q&A

CAR T-Cell Therapy vs Bispecific Antibodies: What's Next for Blood Cancer Treatment?

CAR T-cell therapy and bispecific antibodies have transformed the treatment landscape for many hematologic malignancies, offering new

faculty speaking on stage at LL&M Congress

Can AI Improve Lymphoma Diagnosis?

Artificial intelligence (AI) is rapidly emerging as a powerful tool in lymphoma pathology, helping clinicians and pathologists improve

general session at LL&M Congress

Are We Moving Closer to a Cure for Follicular Lymphoma?

Follicular lymphoma has traditionally been viewed as a chronic, incurable disease characterized by periods of remission and relapse. However

faculty presenting on stage at LL&M Congress

Are Bispecific Antibodies Moving Earlier in DLBCL Treatment?

Bispecific antibodies are rapidly transforming the treatment landscape for diffuse large B-cell lymphoma (DLBCL). Initially developed for

attendees in session at LL&M Congress

AML Transplant Decisions in 2026: Who Still Needs a Stem Cell Transplant?

Allogeneic stem cell transplantation remains one of the most powerful tools for preventing relapse in acute myeloid leukemia (AML), but

Mapping Early Myeloma: How New Research Is Changing Our Understanding of Disease Progression

For years, clinicians have relied on established categories such as monoclonal gammopathy of undetermined significance (MGUS), smoldering

Full room of people at a conference listening to the main stage presentation

HMP Global’s LL&M Winter Symposium to feature faculty experts from University of Miami and Moffitt Cancer Center

Set for February in Miami Beach, the new Symposium continues the 25-year legacy of LL&M Congress and introduces first major hematology event

Dr. Gail Roboz speaking at the LL&M Congress

HMP Global’s LL&M Congress Celebrates 25 Years of Innovation in Hematology Oncology with 25+ New Faculty Experts for 2025

Held October 14-17 in New York City, LL&M Congress offers updates for hematologists, oncologists, APPs, and multidisciplinary cancer teams